Aptamers News and Research

RSS
Modified silicon-based surfaces provide good home to proteins

Modified silicon-based surfaces provide good home to proteins

Built-in blocker - drug and antidote in the same molecule

Built-in blocker - drug and antidote in the same molecule

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

Sirna Therapeutics awarded patent covering large-scale synthesis of RNAi-based therapeutics

New cancer detection method

New cancer detection method

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Targeted drug delivery now possible using nanoparticle-apatamer conjugates

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Targeted drug delivery achieved with nanoparticle-aptamer bioconjugates

Unique arrays of proteins tethered onto self-assembled DNA nanostructures

Unique arrays of proteins tethered onto self-assembled DNA nanostructures

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Pegaptanib (Macugen) is an effective treatment for neovascular age-related macular degeneration

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Researchers have developed a novel drug-antidote pair

Researchers have developed a novel drug-antidote pair

Discovery could lead to the creation of naturally decaffeinated coffee plants

Discovery could lead to the creation of naturally decaffeinated coffee plants

New technology to diagnose, treat deadly diseases

New technology to diagnose, treat deadly diseases

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010